Implications and opportunities of precision medicine in rare malignancies

References

• Keat N, Law K, Seymour M, et al. International rare cancer initiative. Lancet Oncol. 2013; 14:109–110.
   PubMed Web of Science ®Google Scholar
• Schott AF, Welch JJ, Verschraegen CF, et al. The National Clinical Trials Network: conducting successful clinical trials of new therapies for rare cancers. Semin Oncol. 2015;42:731–739.
   PubMed Web of Science ®Google Scholar
• Gatta G, van der Zwan JM, Casali PG, et al.; The RARECARE Working Group. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer. 2011;47(17):2493–2511.
   PubMed Web of Science ®Google Scholar
• Boyd N, Dancey JE, Gilks CB, et al. Rare cancers: a sea of opportunity. Lancet Oncol. 2016;17:e52–e61.
   PubMed Web of Science ®Google Scholar
• Cancer Statistics [Internet]. [cited 2016 May 11]. Available from: Seer.cancer.gov
   Google Scholar
• Teer JK. An improved understanding of cancer genomics through massively parallel sequencing. Transl Cancer Res. 2014;3(3):243–259.
   PubMed Web of Science ®Google Scholar
• Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502(7471):333–339.
   PubMed Web of Science ®Google Scholar
• Feldmeyer L, Gaide O, Speiser DE. Clinical implications of CD8+ T-cell infiltration in frequent and rare cancers. J Investig Dermatol. 2013;133:1929–1932.
   PubMed Web of Science ®Google Scholar
• Orphan Drug Regulations, Final Rule. Food and Drug Administration, Department of Health and Human Services. Fed Registr. 2013;78(113):35117–35135.
   PubMedGoogle Scholar
• Stockklausner C, Lampert A, Hoffmann GF, et al. Novel treatments for rare cancers: the U.S. Orphan Drug Act is delivering-a cross-sectional analysis. Oncologist. 2016;21:1–7.
   PubMed Web of Science ®Google Scholar
• Revised imatinib label [cited 2016 May 22]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021588s037lbl.pdf
   Google Scholar
• Cioffi A, Maki RG. GI stromal tumors: 15 years of lessons from a rare cancer. J Clin Oncol. 2015;33(16):1849–1855.
   PubMed Web of Science ®Google Scholar
• FDA approves imatinib mesylate (Gleevec) as a single agent for the treatment of multiple indications [cited 2016 May 15]. Available from: http://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm094941.htm
   Google Scholar
• Tefferi A, Pardanani A. Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis. Int Hematol. 2004;79:441–447.
   PubMed Web of Science ®Google Scholar
• Duffaud F, Le Cesne A. Imatinib in the treatment of solid tumours. Targ Oncol. 2009;4:45–56.
   PubMed Web of Science ®Google Scholar
• Rutkowski P, Przybył J, Tomasz Świtaj T. Genetics of rare mesenchymal tumors: implications for targeted treatment in DFSP, ASPS, CCS, GCTB and PEComa. Int J Biochem Cell Biol. 2014;53:466–474.
   PubMed Web of Science ®Google Scholar
• Puglisi F, Fontanella C, Amoroso V, et al. Current challenges in HER2-positive breast cancer. Crit Rev Oncol Hematol. 2016;98:211–221.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Sagaert X, Haustermans K, et al. Gastric cancer. Epub ahead of print. doi:10.1016/S0140-6736(16)30354-3.
   Google Scholar
• Bang Y-J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet. 2010;376:687–697.
   PubMed Web of Science ®Google Scholar
• Sartori-Bianchi A, Trusolino L, Martino C, et al. Dual targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): aproof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016. Epub 2016 Apr 20. doi:10.1016/S1470-2045(16)00150-9.
   Web of Science ®Google Scholar
• Siu LL, Conley BA, Boerner S, et al. Next generation sequencing to guide clinical trials. Clin Cancer Res. 2015;21(20):4536–4544.
   PubMed Web of Science ®Google Scholar
• Hyman DM, Puzanov I, Subbiah V, et al. Venmuafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373:726–736.
   PubMed Web of Science ®Google Scholar
• Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483:100–104.
   PubMed Web of Science ®Google Scholar
• Bogaerts J, Sydes MR, Keat N, et al. Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative. Eur J Cancer. 2015;51:271–281.
   PubMed Web of Science ®Google Scholar
• Conley BA, Doroshow JH. Molecular analysis for therapy choice: NCI MATCH. Semin Oncol. 2014;41(3):297–299.
   PubMed Web of Science ®Google Scholar
• NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) Trial [Internet]. [cited 2016 May 15]. Available from: http://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match
   Google Scholar
• Mody RJ, Wu Y-M, Lonigro RJ, et al. Integrative clinical sequencing in the management of refractory or relapsed cancer in youth. JAMA. 2015;314(9):913–925.
   PubMed Web of Science ®Google Scholar
• Sender L, Zabokrtsky KB. Adolescent and young adult patients with cancer: a milieu of unique features. Nat Rev Clin Oncol. 2015;12:465–480.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Rodriguez L, Hirshfield KM, Rojas V, et al. Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers. Gynecol Oncol. 2016;141:2–9.
   PubMed Web of Science ®Google Scholar
• LeTourneau C, Delord J-P, Goncalves A, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicenter, open-label, proof-of-concept, randomized, controlled phase 2 trial. Lancet Oncol. 2015;16:1324–1334.
   PubMed Web of Science ®Google Scholar
• Sandrucci S, Gatta G, Dei Tos AP, et al. Specialized teams or specialist networks for rare cancers? Eur J Surg Oncol. 2015;41:1115–1117.
   PubMed Web of Science ®Google Scholar
• Prasad V, Oseran A. Do we need randomised trials for rare cancers? Eur J Cancer. 2015;51:1355–1357.
   PubMed Web of Science ®Google Scholar
• Damodaran S, Berger MF, Roychowdhury S. Clinical tumor sequencing: opportunities and challenges for precision cancer medicine. In: Don S, Dizon MD, editors. ASCO Educational Book. Alexandria (VA): American Association of Clinical Oncology; 2015. p. e175–e182.
   Google Scholar
• Alizedeh AA, Aranda V, Bardelli A, et al. Toward understanding and exploiting tumor heterogeneity. Nat Med. 2015;21(8):846–853.
   PubMed Web of Science ®Google Scholar
• Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221–223.
   PubMed Web of Science ®Google Scholar
• Wagle N, Grabiner BC, VanAllen EM, et al. Activating mTOR mutations in a patient with a an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 2014;4(5):546–553.
   PubMed Web of Science ®Google Scholar
• Wang K, Russell JS, McDermott JD, et al. Profiling of 149 salivary duct carcinomas, carcinoma ex pleomorphic adenomas, and adenocarcinomas, not otherwise specified reveals actionable genomic alterations. Clin Cancer Res. 2016. Epub ahead of print. doi:10.1158/1078-0432.CCR-15-2568.
   Web of Science ®Google Scholar
• Andersson MK, Stenman G. The landscape of gene fusions and somatic mutations in salivary gland neoplasms – implications for diagnosis and therapy. Oral Oncol. 2016;57:63–69.
   PubMed Web of Science ®Google Scholar